TIGD5 Antibody

What is TIGD5 and why is it relevant to research?

TIGD5 (tigger transposable element derived 5) belongs to the tigger subfamily of the pogo superfamily of DNA-mediated transposons in humans. It encodes a nuclear protein with DNA-binding motifs, suggesting potential roles in gene regulation. The protein has gained research interest due to its:

• Associations with neurodevelopmental disorders (particularly ASD)

• Involvement in cancer biology (notably ovarian cancer)

• Identification as a proteasome substrate

• Location on chromosome 8q24, a region frequently amplified in various cancers

The calculated molecular weight of TIGD5 is 593 amino acids (65 kDa), while the observed molecular weight typically ranges between 65-70 kDa in laboratory analyses .

What types of TIGD5 antibodies are available for research applications?

Available TIGD5 antibodies include:

Most commercially available antibodies are unconjugated polyclonal antibodies raised in rabbits against human TIGD5 protein or peptide epitopes. They primarily show reactivity with human, mouse, and rat samples, making them suitable for comparative studies across these species .

What are the validated applications for TIGD5 antibodies?

Current research demonstrates that TIGD5 antibodies have been validated for:

• Western Blot (WB): The predominant application, typically using dilutions of 1:500-1:2000

• ELISA: Validated for detection of TIGD5 in immunoassays

• Immunohistochemistry (IHC): Reported for some antibodies but with fewer validation studies

Proteomic studies have successfully employed TIGD5 antibodies in:

• Detection of TIGD5 as a proteasome substrate

• Analysis of TIGD5 protein stability in cycloheximide chase experiments

• Investigation of TIGD5 expression in ovarian cancer models

What are the optimal western blot conditions for TIGD5 detection?

Based on published protocols and commercial recommendations:

Sample Preparation:

• Cell lysates from HeLa cells have shown consistent TIGD5 detection

• For tissue samples, optimization of extraction buffers may be necessary

Protocol Parameters:

• Recommended antibody dilutions: 1:500-1:1000 for most applications

• Expected band size: 65-70 kDa

• Storage buffer: PBS with 0.02% sodium azide and 50% glycerol (pH 7.3)

• Storage conditions: -20°C for long-term stability; aliquoting recommended for repeated use

Controls:

• Positive control: HeLa cell lysate shows reliable expression

• Validation: Some antibodies have been validated in publications examining TIGD5 as a proteasome substrate

How can researchers verify TIGD5 antibody specificity?

Ensuring antibody specificity is critical for reliable results. Recommended verification approaches include:

• Knockout/knockdown validation:

  • Generate TIGD5 knockout or knockdown cell lines using CRISPR-Cas9 or siRNA technology

  • Compare antibody signal between wild-type and knockout/knockdown samples

• Overexpression validation:

  • Express tagged TIGD5 in cell lines

  • Confirm co-localization of signal from anti-TIGD5 antibody and anti-tag antibody

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Observe elimination of specific signal in Western blot or immunostaining

• Multi-antibody verification:

  • Use antibodies targeting different epitopes of TIGD5

  • Confirm consistent detection patterns

What experimental conditions affect TIGD5 detection in cellular systems?

Several experimental factors can influence TIGD5 detection:

• Proteasome inhibition:

  • Treatment with MG132 (20 μM for 4 hours) enhances TIGD5 detection due to its nature as a proteasome substrate

  • In cycloheximide chase experiments, TIGD5 showed rapid degradation that was inhibited by proteasome blockers

• Cell type considerations:

  • Expression levels vary across cell types; HeLa cells show reliable expression

  • Ovarian cancer cell lines demonstrated altered TIGD5 expression patterns compared to normal cells

• Fixation and extraction methods:

  • For cellular immunostaining, optimization of fixation protocols may be necessary

  • Nuclear localization may require specific extraction methods for complete recovery

How is TIGD5 implicated in cancer biology, particularly ovarian cancer?

TIGD5 exhibits interesting dual characteristics in cancer research:

• Genomic amplification:

  • The TIGD5 gene is located on chromosome 8q24.3, a region frequently amplified in ovarian cancers

  • TIGD5 often co-amplifies with the MYC oncogene (located at 8q24.21)

  • High TIGD5 mRNA expression correlates with poor prognosis in ovarian cancer patients

• Tumor suppressive function:

  • Despite its amplification, functional studies revealed TIGD5 overexpression suppressed growth, adhesion, and invasion of ovarian cancer cell lines in vitro

  • TIGD5 overexpression reduced tumor growth in xenografted nude mice

  • This suggests TIGD5 may function as a tumor suppressor rather than an oncogene, despite being in an amplified region

These seemingly contradictory findings highlight the complex role of TIGD5 in cancer biology and suggest it may be part of compensatory mechanisms activated during cancer progression.

What is known about TIGD5's association with autism spectrum disorder (ASD)?

Research has identified TIGD5 as a potential risk gene for ASD:

• Genetic association:

  • The TIGD5 rs75547282 polymorphism was associated with increased risk of ASD under the dominant model (OR = 1.37, 95% CI = 1.09-1.72, P = 0.006) in a Han Chinese population study

  • This finding emerged from a convergent functional genomics (CFG) approach that prioritized candidate genes using multiple lines of evidence

• Functional impact:

  • The T allele of rs75547282 activated the expression of TIGD5 compared with the C allele in dual-luciferase reporter assay

  • This suggests altered TIGD5 expression may contribute to ASD pathophysiology

• Research limitations:

  • The statistical power of the study was limited (5.2%)

  • Larger population samples are needed to increase statistical power and confirm findings

  • Mechanistic studies linking TIGD5 function to neuronal development or function remain limited

How is TIGD5 involved in protein degradation pathways?

TIGD5 has been identified as a proteasome substrate through advanced proteomic approaches:

• Proteasome interaction:

  • ProteasomeID methodology identified TIGD5 as a protein exclusively enriched upon MG132 (proteasome inhibitor) treatment

  • Cycloheximide chase experiments validated TIGD5 as a proteasome substrate

• Stability regulation:

  • TIGD5 appears to undergo relatively rapid proteasomal degradation under normal conditions

  • This suggests its expression levels may be tightly regulated post-translationally

• Research implications:

  • The identification of TIGD5 as a proteasome substrate provides insight into its cellular regulation

  • Transient expression patterns could be critical for its proposed tumor suppressor functions

  • Proteasome inhibitors may be useful tools for studying TIGD5 biology by stabilizing the protein

What are the best approaches for studying TIGD5 DNA-binding properties?

As a protein with DNA-binding features, investigating TIGD5's interaction with genetic material requires specialized techniques:

• Chromatin immunoprecipitation (ChIP):

  • Use validated TIGD5 antibodies for chromatin pulldown experiments

  • Consider crosslinking optimization due to potentially transient DNA interactions

  • Control experiments with TIGD5 knockdown/knockout are essential for specificity verification

• Electrophoretic mobility shift assay (EMSA):

  • Can be performed with recombinant TIGD5 protein and candidate DNA sequences

  • Has potential to identify sequence-specific binding motifs

• DNA affinity precipitation (DNAP):

  • May reveal specific DNA sequences bound by TIGD5

  • Can be coupled with mass spectrometry to identify TIGD5-associated protein complexes

• Reporter assays:

  • Similar to those used in the ASD study , can reveal TIGD5's effect on transcriptional regulation

  • Design experiments to test both activating and repressive functions

How can researchers overcome common challenges in TIGD5 protein detection?

Several technical challenges may arise when working with TIGD5:

• Low endogenous expression:

  • Consider proteasome inhibition (MG132, 20 μM, 4-6 hours) to stabilize protein levels

  • Enrich nuclear fractions when working with tissue samples

  • Use immunoprecipitation to concentrate protein before detection

• Non-specific antibody binding:

  • Increase blocking stringency (5% BSA or milk in TBST)

  • Optimize antibody dilutions (typically starting at 1:500-1:1000)

  • Consider secondary antibody-only controls to assess background

• Signal variability across samples:

  • Standardize lysate preparation protocols

  • Normalize loading with multiple housekeeping controls

  • Consider quantifying TIGD5 mRNA levels in parallel to correlate with protein expression

What are the emerging techniques for studying TIGD5 function in cellular contexts?

As research on TIGD5 advances, several cutting-edge approaches show promise:

• CRISPR-based methodologies:

  • CRISPR knockouts to assess loss-of-function phenotypes

  • CRISPR activation (CRISPRa) to upregulate endogenous TIGD5

  • CRISPR interference (CRISPRi) for targeted repression

  • CRISPR base editing for modeling specific polymorphisms like rs75547282

• Live-cell imaging approaches:

  • Fluorescent tagging (e.g., GFP-TIGD5) for dynamics studies

  • Consider photoactivatable or photoswitchable tags for pulse-chase experiments

  • FRAP (Fluorescence Recovery After Photobleaching) to study mobility and binding kinetics

• Proximity labeling techniques:

  • BioID or TurboID fusions to identify proximal interacting proteins

  • Could reveal TIGD5's involvement in specific nuclear complexes

  • May help identify both DNA and protein interaction partners

• Single-cell analysis:

  • Assess heterogeneity of TIGD5 expression in complex tissues

  • Combine with spatial transcriptomics to understand expression patterns in tissue context

  • Particularly relevant for studying TIGD5 in developmental contexts or disease states

What are the most reliable TIGD5 antibody validation indicators?

When selecting antibodies for TIGD5 research, consider these validation indicators:

• Published validation data:

  • Antibodies used in peer-reviewed publications (e.g., Proteintech 13644-1-AP has been cited in publications)

  • Demonstrated specificity in knockout/knockdown experiments

  • Consistent detection at the expected molecular weight (65-70 kDa)

• Validation across applications:

  • Confirmed functionality in multiple techniques (WB, ELISA, IHC)

  • Consistent performance across different cell types/tissues

  • Lot-to-lot consistency data from manufacturers

• Cross-reactivity assessment:

  • Tested reactivity with human, mouse, and rat TIGD5

  • Specificity testing against related proteins in the TIGD family

  • Absence of non-specific bands in immunoblotting

How should researchers interpret contradictory findings regarding TIGD5 function?

The literature contains apparent contradictions about TIGD5's role, particularly in cancer. When navigating conflicting data:

• Context-dependent functions:

  • Consider cellular context specificity (cancer type, stage, genetic background)

  • TIGD5 may have different roles in different tissues or developmental stages

  • The paradoxical tumor suppressor function in amplified regions suggests complex biology

• Methodological differences:

  • Evaluate the specific techniques used in conflicting studies

  • Overexpression vs. knockdown approaches may reveal different aspects of function

  • In vitro vs. in vivo models may yield different results

• Research gaps to address:

  • Dose-dependent effects warrant investigation (subtle vs. strong overexpression)

  • Temporal aspects of TIGD5 function remain poorly understood

  • Interaction with other genes in the 8q24 amplicon (particularly MYC) needs further study

What are the current limitations in TIGD5 research tools and knowledge?

Despite progress, several limitations affect TIGD5 research:

• Technical limitations:

  • Limited availability of validated monoclonal antibodies

  • Few antibodies validated for immunoprecipitation or ChIP applications

  • Lack of characterized animal models specifically targeting TIGD5

• Knowledge gaps:

  • Incomplete understanding of physiological function

  • Limited data on tissue-specific expression patterns

  • Unknown regulatory mechanisms controlling TIGD5 expression

  • Unclear relationship between TIGD5's DNA-binding capability and its cellular functions

• Future research priorities:

  • Development of inducible expression/knockdown systems

  • Identification of TIGD5 binding partners and DNA targets

  • Exploration of post-translational modifications regulating TIGD5

  • Further investigation of its role in neurodevelopment and cancer biology